XM does not provide services to residents of the United States of America.

Janux Therapeutics surges on upbeat trial data for prostate cancer therapy



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Janux Therapeutics surges on upbeat trial data for prostate cancer therapy</title></head><body>

Updates shares in paragraphs 2, adds analyst comments in paragraphs 7 and 8

By Pratik Jain

Feb 27 (Reuters) -Janux Therapeutics shares JANX.O more than doubled in value on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced form of prostate cancer.

Its shares hit a record high of $41.22, after declining 18.53% in 2023 and were on track to add more than $1.2 billion to its market capitalization, if gains hold.

The candidate, JANX007, reduced prostate-specific (PSA) antigen levels in a majority of the 23 patients who received the drug, the company said late on Monday, adding that deeper reductions were observed at higher doses.

PSA is a protein produced by the prostate gland and used as a biomarker to diagnose and follow prostate cancer.

TD Cowen analyst Marc Frahm said the data establishes that Janux's prostate cancer therapy, JANX007, has multi-billion-dollar potential.

Janux also reported interim early-stage data for another experimental therapy, JANX008, in advanced or metastatic solid tumors patients known to express high levels of a protein that helps cancer cells grow.

H.C. Wainwright analyst Swayampakula Ramakanth said both drugs showed encouraging anti-tumor efficacy and the treatments could be the "best-in-class" if they continue to be successful in future studies.

"While the data was from a small set of patients, it was encouraging to note that both products were relatively safe with no patient experiencing higher than grade 2 CRS...," Ramakanth said.

Cytokine Release Syndrome (CRS), was also observed in patients in both the studies, but Janux said it was mild and temporary, and was quickly managed with treatment.

CRS is an immune system over-response and a major toxicity issue that has led to discontinuation of multiple T-cell engager clinical candidates.

Janux, which develops tumor-activated immunotherapies to treat cancer, debuted on the Nasdaq in 2021.



Reporting by Pratik Jain in Benagluru

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.